Lung Cancer
Lung cancer, also known as lung carcinoma, is a malignant tumor that begins in the cells of the lungs, typically caused by genetic damage from smoking or inhaling harmful chemicals. There are two main types: small cell lung cancer and non-small cell lung cancer, the latter including adenocarcinoma and squamous cell carcinoma, which can spread throughout the lung and to other parts of the body if not treated.
Health Outcomes
- Accelerated Recovery of Chemotherapy-Induced Myelosuppression
- Activated p53/BAX-Mediated DNA Damage Response
- Additive Antitumorigenic Effect
- Cancer Treatment Support
- Decreased Granulocyte Count in Lungs
- Decreased Lower Respiratory Quotient
- Delayed Tumor Onset
- Downregulated Hippo Pathway Kinase Activity
- Enhanced Anticancer Capacity
- Enhanced Antitumor Immune Response
- Enhanced Antitumor Immunity
- Enhanced CD8+ T Cell Infiltration
- Enhanced CD8+ T Cell Recruitment
- Enhanced Caspase-3 Activity
- Enhanced Cell Viability
- Enhanced Cytolytic Response of CD8+ T Cells
- Enhanced DNA Repair
- Enhanced Health Promotion
- Enhanced Natural Killer Cell Activity
- Enhanced Natural Killer Cell Tumor Killing Activity
- Enhanced Natural Killer Cell Tumoricidal Activity
- Enhanced Pro-Apoptotic MAPK Signaling
- Enhanced Tumor-Targeted Drug Delivery
- Genome Sequencing / Genome Characterization
- Identification of FDA Approved Drug Target Regulators
- Improved Antitumor Response
- Improved Cancer-Related Health Outcome
- Improved Cell Viability
- Improved Chemotherapy Efficacy
- Improved Clinical Success
- Improved Effectiveness in Cancer Treatment
- Improved Efficacy Rate
- Improved Histopathological Findings in Lungs
- Improved Histopathological Indicators
- Improved Karnofsky Performance Status
- Improved NK-Cell Cytotoxicity
- Improved Natural Killer Cell Activation
- Improved Natural Killer Cell Activity
- Improved Natural Killer Cell Tumoricidal Activity
- Improved Objective Response Rate
- Improved Oncolytic Virotherapy Efficacy
- Improved Overall Survival
- Improved Pathological Response
- Improved Post-Challenge Survival
- Improved Progression-free Survival
- Improved Recovery in Immunocompromised Individuals
- Improved Remission
- Improved Resistance to Sodium Selenite
- Improved Response Rate
- Improved Response to Immune Checkpoint Inhibitor Therapy
- Improved Response to PD-1 Immunotherapy
- Improved Survival
- Improved Survival Capacity
- Improved Survival Rate
- Improved Therapeutic Potential
- Improved Treatment Response Rate
- Improved Tumor Response
- Inactivated Other Receptor Tyrosine Kinase Activity
- Incidence of Death
- Increased Anti-Tumor Activity
- Increased Antiangiogenic Activity
- Increased Anticancer Activity
- Increased Anticancer Treatment Adherence
- Increased Apoptosis
- Increased Binding of Carcinogenic Compounds
- Increased Cell Death
- Increased Cell Division
- Increased Cellular Adhesion
- Increased Chromosomal Instability
- Increased Cure Rate after Conventional Treatment
- Increased Hydrogen Peroxide Production
- Increased IL-8 Levels at 24 Hours
- Increased Intratumoral Accumulation
- Increased Intratumoral CD8+ T-cell Expansion
- Increased Lesion Detection Rate
- Increased Lung CD3+CD4+ IFN-γ+ T Cells
- Increased Mitogenic Activity
- Increased NK Cell Activity
- Increased Polyamine Production
- Increased Pro-apoptotic Factor Levels
- Increased Proportion of Responders
- Increased Protease Levels
- Increased Reduced Glutathione Level
- Increased Survival Rate
- Increased Survival Time
- Increased Survival in Tumor-Bearing Mice
- Increased TIMP-1 Levels
- Increased Telomere Length
- Increased Tissue Invasion
- Increased Transforming Growth Factor-β Levels
- Increased VEGF Level
- Increased Viable Cell Antioxidant Activity
- Increased mTORC1 Activation
- Inhibited EGF Receptor Signaling
- Inhibited Epithelial-Mesenchymal Transition
- Inhibited PI3K/AKT Pathway
- Maintained Natural Killer Cell Activity
- Mitigated Adverse Impacts of IoNPs on Physiological Processes
- No Improvement in Objective Cancer Treatment Response
- No Mutagenicity
- No Serious Treatment-Related Adverse Events
- Normalized Expression of rhoB Gene
- Overall Treatment Success
- Reduced Apoptosis Due to Carcinogens
- Reduced Bax/Bcl-2 Ratio
- Reduced Benzo(a)pyrene Levels
- Reduced CEA Levels
- Reduced Cancer Activity
- Reduced Cancer Progression
- Reduced Cancer Risk
- Reduced Cancer-Related Inflammation
- Reduced Cancer-Specific Mortality
- Reduced Carcinogenesis
- Reduced Caspase-3 Activity
- Reduced Cause-Specific Mortality
- Reduced Cell Adhesion
- Reduced Cell Apoptosis
- Reduced Cell Viability
- Reduced Chemotherapy Side Effects
- Reduced Cumulative Incidents of CIDs in Smokers
- Reduced Cytotoxicity of BaP
- Reduced DNA Damage
- Reduced Epithelial Cell Apoptosis
- Reduced Epithelial-Mesenchymal Transition
- Reduced Exposure to Harmful Substances
- Reduced Expression of STAT3-Dependent Tumor-Associated Genes
- Reduced Genotoxicity
- Reduced ICU Length of Stay
- Reduced IkappaB Alpha Degradation
- Reduced Lifespan
- Reduced Mortality
- Reduced Pulmonary Metastasis
- Reduced Risk of Cancer
- Reduced Survival Rate
- Reduced Total Cells in Bronchoalveolar Lavage Fluid
- Reduced Tumor Downstaging
- Reduced Tumor Formation
- Reduced Tumor Grade
- Reduced Tumor Growth
- Reduced Tumor Growth Rate
- Reduced Tumor Incidence
- Reduced Tumor Multiplicity
- Reduced Tumor Risk
- Reduced Tumor Stage
- Reduced Tumor Volume
- Regulated miR-130a-5p Levels
- Shifted Tumor-Associated Macrophages Toward Pro-Inflammatory M1 Polarization
- Stabilized Natural Killer Cell Activity
- Suppressed Tumor Growth
- Suppressed Wnt/β-catenin Signaling
- Targeted Tumor Reduction